The cost is very dependent on where people live and what the availability of drug coverage is, which is why one of our recommendations is broad coverage of these first-line medications for opioid agonist therapy.
In my province, buprenorphine, naloxone and methadone, as daily options, as well as the injectable buprenorphine, are covered if people are on social assistance or if they have coverage through treaty status. Otherwise, people have to pay for them, and they are relatively similar in terms of cost.